News

Injectable therapy shows consistent benefits across high-risk ATTR-CM groupsNew analyses back the use of the approved therapy Amvuttra (vutrisiran) as an initial…

–    Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)  ––   CR rate now 95% (19 of 20…

Multiparametric scores are effective for validating the AL score and increased wall thickness (IWT) scores in AL amyloidosis, according to a study being presented…

The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics,…

The injection therapy Wainua (eplontersen) “offers a vital ray of hope” for people living with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN),…

This CardiaCast episode explores the latest advances in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at ACC.26, with a focused review of newly released…

The investigational PET tracer iodine-124 (I-124) evuzamitide met its primary endpoints for the diagnosis of cardiac amyloidosis, including transthyretin-mediated…

Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiomyopathy that may occur in hereditary or wild-type forms. Although more than 150…

The association between amyloidosis and aortic valve stenosis has attracted considerable international attention. However, when researchers at Umeå University…

A new diagnostic tool developed at the University of Tennessee Health Sciences may soon make it significantly easier for physicians to detect cardiac amyloidosis, a…